Introduction. Low molecular weight heparin (LMWH) is preferred for @entity1211 ( @entity1211 ). Many providers monitor LMWH with anti-Xa levels, despite little validation on correspondence with @entity1 outcome. Methods. This is a retrospective, single institution study of anti-Xa measurement in malignancy-associated @entity715 . Cases were identified using the Electronic Data Warehouse, and inclusion was confirmed by two independent reviewers. Malignancy type, thrombotic history, measurement rationale and accuracy, clinical context, and management changes were evaluated. Results. 167 cases met inclusion criteria. There was no clear rationale for anti-Xa testing in 56%. @entity8 (10%), documented or suspected recurrent @entity715 despite anticoagulation (9%), and @entity548 (6%) were the most common reasons for testing. Incorrect measurement occurred in 44%. @entity8 was not a significant impetus for testing, as 70% had a GFR > 60. BMI > 30 was present in 40%, and 28% had a BMI < 25. Clinical impact was low, as only 11% of @entity1 had management changes. Conclusions. Provider education in accuracy and rationale for anti-Xa testing is needed. Our study illustrates uncertainty of interpretation and clinical impact of routine anti-Xa testing, as management was affected in few @entity1 . It is not yet clear in which clinical context providers should send anti-Xa levels.

Clinical Use of Anti-Xa Monitoring in Malignancy-Associated XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['Impaired renal function', 'Renal impairment'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['malignancy-associated venous thromboembolism', 'VTE']
@entity715 :: (MESH:D013927,Disease) :: ['Thrombosis']
